ARGX
argenx NV ADR
NASDAQ: ARGX · HEALTHCARE · BIOTECHNOLOGY
$776.02
+0.13% today
Updated 2026-04-29
Market cap
$48.76B
P/E ratio
39.81
P/S ratio
11.51x
EPS (TTM)
$19.60
Dividend yield
—
52W range
$510 – $935
Volume
0.3M
argenx NV ADR (ARGX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.98M | $-11.09M | $-9.12M | $-6.37M | $-15.19M | $11.15M | $-43.84M | $-61.59M | $151.63M | $-398.46M | $-606.81M | $-862.81M | $-420.33M | $-82.75M | $850.49M |
| Capital expenditures | $308000.00 | $115000.00 | $89756.00 | $225000.00 | $305000.00 | $906000.00 | $421000.00 | $782000.00 | $46.73M | $5.14M | $121.43M | $103.82M | $43.81M | $68.30M | $6.18M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $257922.00 | $1.01M | $338313.00 | $1.16M | $2.48M | $3.00M | $5.12M | $21.94M | $44.24M | $96.93M | $179.37M | $157.03M | $232.97M | $235.18M | $248.08M |
| Free cash flow | $-4.29M | $-11.20M | $-9.21M | $-6.59M | $-15.50M | $10.24M | $-44.27M | $-62.37M | $104.89M | $-403.60M | $-728.25M | $-966.63M | $-464.14M | $-151.05M | $844.30M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | $5.47M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |